Weiss Ratings Reaffirms “Sell (E)” Rating for Mainz Biomed (NASDAQ:MYNZ)

Mainz Biomed (NASDAQ:MYNZ)‘s stock had its “sell (e)” rating reiterated by analysts at Weiss Ratings in a research report issued on Tuesday,Weiss Ratings reports.

Mainz Biomed Stock Down 3.9%

Shares of NASDAQ MYNZ opened at $1.48 on Tuesday. Mainz Biomed has a 52-week low of $1.28 and a 52-week high of $14.39. The business’s 50 day moving average is $1.63 and its two-hundred day moving average is $2.05. The firm has a market cap of $8.01 million, a price-to-earnings ratio of -0.02 and a beta of 0.25. The company has a quick ratio of 0.43, a current ratio of 0.52 and a debt-to-equity ratio of 0.44.

Institutional Trading of Mainz Biomed

An institutional investor recently raised its position in Mainz Biomed stock. Armistice Capital LLC grew its holdings in Mainz Biomed NV (NASDAQ:MYNZ) by 45.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 285,000 shares of the company’s stock after purchasing an additional 88,400 shares during the quarter. Armistice Capital LLC owned 6.23% of Mainz Biomed worth $402,000 at the end of the most recent reporting period.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.